Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

The selective serotonin reuptake inhibitors (SSRIs) are the most extensively studied of the newer antidepressants and are increasingly being used as first-line treatment for depression (Anderson et al, 2000). In this article we concentrate on issues that need to be taken into account when selecting one of the five SSRIs marketed in the UK (citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) for individual patients. We have concentrated on treatment of depression and have not reviewed their use in anxiety disorders because comparative data are lacking.

Download Full-text

Selective serotonin reuptake inhibitors for depression?

Drug and Therapeutics Bulletin ◽

10.1136/dtb.31.15.57 ◽

1993 ◽

Vol 31 (15) ◽

pp. 57-58

Keyword(s):

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Depressive Illness ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin ◽

New Class ◽

The Past ◽

The Uk

In the past decade a new class of drugs, the selective serotonin reuptake inhibitors (SSRIs), has become available for the treatment of patients with depressive illness. Four SSRIs, fluoxetine (Prozac – Dista), fluvoxamine (Faverin – Duphar), paroxetine (Seroxat – Smithkline Beecham) and sertraline (Lustral – Invicta/Pfizer), are marketed in the UK. How do they compare with the older and cheaper tricyclics?

Download Full-text

Vortioxetine for depression: the evidence for its current use in the UK

BJPsych Advances ◽

10.1192/bja.2018.62 ◽

2018 ◽

Vol 25 (1) ◽

pp. 3-6

Author(s):

Riccardo De Giorgi

Keyword(s):

Side Effects ◽

Mechanism Of Action ◽

Pharmacological Treatment ◽

Response To Treatment ◽

Line Treatment ◽

Clinical Context ◽

First Line ◽

Treatment Of Depression ◽

The Uk ◽

First Line Treatment

SUMMARYThe pharmacological treatment of depression is often hampered by side-effects and unsatisfactory response to treatment. Vortioxetine is one of the newest antidepressants on the market, purportedly with a different mechanism of action compared with other antidepressants. This month's Cochrane Corner review examines the evidence available for the use of vortioxetine as a first-line treatment for depression in adults. This commentary puts the Cochrane review's findings into their clinical context and revises them in view of earlier and later studies.DECLARATION OF INTERESTNone.

Download Full-text

Multiple serotonergic paths to antidepressant efficacy

Journal of Neurophysiology ◽

10.1152/jn.01093.2012 ◽

2013 ◽

Vol 109 (9) ◽

pp. 2245-2249 ◽

Cited By ~ 5

Author(s):

Pierre-Eric Lutz

Keyword(s):

Serotonin Reuptake ◽

Animal Studies ◽

Serotonin Receptor ◽

Selective Serotonin Reuptake Inhibitors ◽

Serotonin Reuptake Inhibitors ◽

Receptor Subtypes ◽

Line Treatment ◽

First Line ◽

Antidepressant Efficacy ◽

First Line Treatment

Depression is a leading cause of disability worldwide. Brain mechanisms underlying the clinical antidepressant efficacy of selective serotonin reuptake inhibitors (SSRI), currently the first-line treatment, remain poorly understood. Recent animal studies have implicated multiple serotonin receptor subtypes in SSRI response, opening new therapeutic perspectives.

Download Full-text